Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Shareholder Meeting (November 2023)
10 slides from Bio-gene Technology's shareholder meeting presentation, Nov 23, 2023
Slide 1: Bio-Gene Technology Limited Annual General Meeting – CEO Presentation
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED 23 NOVEMBER 2023 Annual General Meeting – CEO Presentation PRESENTED BY Tim Grogan CEO & MANAGING DIRECTOR
Slide 2: Annual General Meeting – CEO's Address
ANNUAL GENERAL MEETING CEO’s Address Tim Grogan 2
Slide 3: Agenda
AGENDA 1. Bio-Gene: • Business model • Success – what really matters? • Bio-Gene’s Active ingredients 2. FY23 Performance Highlights 3. Public Health & Crop Protection 4. Bio-Gene’s Strategic Priorities 3
Slide 4: Bio-Gene's Business Model
BIO-GENE’S BUSINESS MODEL FY 2023 FY 2027 FY 2031 Active ingredients first Expanding commercialised product Registration and Commercial registrations driving significant increase in royalty development stage Products developed can go to payments Licence fees, milestone payments market Hi
Slide 5: Success - What Really Matters?
SUCCESS - WHAT REALLY MATTERS? Bio-Gene’s Progress & De-Risking: QCIDE & FLAVOCIDE 1. Can you make it? 3. Can you sell it? • QCIDE – AI & formulated • Regulatory progress (e.g. tox and env. safety profile) • FLAVOCIDE – AI & formulated • Product development (milestone payments) • Capacity • Partneri
Slide 6: Bio-Gene's Active Ingredients: A Step-Change for Resistant Pest Control
BIO-GENE’S ACTIVE INGREDIENTS: A STEP-CHANGE FOR RESISTANT PEST CONTROL • Novel Mode of Action (MoA) • Positive efficacy • Last new MoA commercialised in 2008, with current sales of US$2.3bn QCIDETM FLAVOCIDETM • Natural compound Natural Compound Nature Identical Compound • Ecologically acceptable A
Slide 7: FY23 Performance Highlights
FY23 PERFORMANCE HIGHLIGHTS Key developments provide a clear path to formulation, registrations and commercialisation FY23 Key partnership, patent and achievements STK Clarke Synergy GRDC Patent Agreement extension results support protection FY23 Financials Key achievements subsequent year end Opera
Slide 8: Mosquitos - A Major Threat to Public Health
MOSQUITOS - A MAJOR THREAT TO PUBLIC HEALTH Developing the next generation of insecticides to effectively control resistant insects and pests enhancing global public health, with low toxicity for human health and the environment. The scale of the problem • WHO estimates more than half the world is a
Slide 9: Bio-Gene's Strategic Priorities
BIO-GENE’S STRATEGIC PRIORITIES 1. Speed: • FLAVOCIDE AI & QCIDE AI - Pre-registration manufacturing & safety studies 2. Focussed Product Development: • Focussed development/product pipeline & partnered programs (both stand-alone & combination products) 3. Commercial Validation: • Further commercial
Slide 10: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation
Bio-gene Technology — Shareholder Meeting (November 2023) on 6ix